Life style; personal characteristics
| Characteristics | Margins | Periods | Drug use, 12 years or older Drugs excluding cannabis, laughing gas Last month (%) | Drug use, 12 years or older Drugs excluding cannabis, laughing gas Last year (%) | Drug use, 12 years or older Drugs excluding cannabis, laughing gas Ever (%) | Drug use, 12 years or older Use of laughing gas Last month (%) | Drug use, 12 years or older Use of laughing gas Last year (%) | Drug use, 12 years or older Use of laughing gas Ever (%) | Drug use, 12 years or older Other drugs excluding laughing gas Last month (%) | Drug use, 12 years or older Other drugs excluding laughing gas Last year (%) | Drug use, 12 years or older Other drugs excluding laughing gas Ever (%) | Drug use, 12 years or older Drugs total, excluding laughing gas Last month (%) | Drug use, 12 years or older Drugs total, excluding laughing gas Last year (%) | Drug use, 12 years or older Drugs total, excluding laughing gas Ever (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total persons | Value | 2025 | . | . | . | 0.1 | 0.4 | 6.6 | . | . | . | . | . | . |
| Total persons | Lower bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.3 | 6.0 | . | . | . | . | . | . |
| Total persons | Upper bound 95% confidence interval | 2025 | . | . | . | 0.2 | 0.6 | 7.2 | . | . | . | . | . | . |
| Sex: Male | Value | 2025 | . | . | . | 0.2 | 0.4 | 8.3 | . | . | . | . | . | . |
| Sex: Male | Lower bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.3 | 7.4 | . | . | . | . | . | . |
| Sex: Male | Upper bound 95% confidence interval | 2025 | . | . | . | 0.4 | 0.7 | 9.3 | . | . | . | . | . | . |
| Sex: Female | Value | 2025 | . | . | . | 0.1 | 0.4 | 4.9 | . | . | . | . | . | . |
| Sex: Female | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.2 | 4.2 | . | . | . | . | . | . |
| Sex: Female | Upper bound 95% confidence interval | 2025 | . | . | . | 0.2 | 0.6 | 5.6 | . | . | . | . | . | . |
| Age: 0 to 3 years | Value | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 0 to 3 years | Lower bound 95% confidence interval | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 0 to 3 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 4 to 11 years | Value | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 4 to 11 years | Lower bound 95% confidence interval | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 4 to 11 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 12 to 15 years | Value | 2025 | . | . | . | 0.0 | 0.2 | 0.2 | . | . | . | . | . | . |
| Age: 12 to 15 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 0.0 | . | . | . | . | . | . |
| Age: 12 to 15 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | 1.2 | 1.2 | . | . | . | . | . | . |
| Age: 16 to 19 years | Value | 2025 | . | . | . | 0.7 | 1.5 | 3.5 | . | . | . | . | . | . |
| Age: 16 to 19 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.2 | 0.7 | 2.1 | . | . | . | . | . | . |
| Age: 16 to 19 years | Upper bound 95% confidence interval | 2025 | . | . | . | 2.4 | 3.3 | 5.5 | . | . | . | . | . | . |
| Age: 20 to 29 years | Value | 2025 | . | . | . | 0.4 | 1.0 | 20.8 | . | . | . | . | . | . |
| Age: 20 to 29 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.5 | 18.3 | . | . | . | . | . | . |
| Age: 20 to 29 years | Upper bound 95% confidence interval | 2025 | . | . | . | 1.0 | 1.9 | 23.4 | . | . | . | . | . | . |
| Age: 30 to 39 years | Value | 2025 | . | . | . | 0.1 | 0.6 | 14.4 | . | . | . | . | . | . |
| Age: 30 to 39 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.3 | 12.5 | . | . | . | . | . | . |
| Age: 30 to 39 years | Upper bound 95% confidence interval | 2025 | . | . | . | 0.6 | 1.3 | 16.6 | . | . | . | . | . | . |
| Age: 40 to 49 years | Value | 2025 | . | . | . | 0.1 | 0.4 | 5.3 | . | . | . | . | . | . |
| Age: 40 to 49 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.2 | 4.1 | . | . | . | . | . | . |
| Age: 40 to 49 years | Upper bound 95% confidence interval | 2025 | . | . | . | 1.0 | 1.2 | 6.8 | . | . | . | . | . | . |
| Age: 50 to 54 years | Value | 2025 | . | . | . | 0.0 | 0.0 | 3.2 | . | . | . | . | . | . |
| Age: 50 to 54 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 2.0 | . | . | . | . | . | . |
| Age: 50 to 54 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | 5.0 | . | . | . | . | . | . |
| Age: 55 to 64 years | Value | 2025 | . | . | . | 0.0 | 0.1 | 0.9 | . | . | . | . | . | . |
| Age: 55 to 64 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 0.5 | . | . | . | . | . | . |
| Age: 55 to 64 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | 0.5 | 1.7 | . | . | . | . | . | . |
| Age: 65 to 74 years | Value | 2025 | . | . | . | 0.0 | 0.0 | 0.2 | . | . | . | . | . | . |
| Age: 65 to 74 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 0.0 | . | . | . | . | . | . |
| Age: 65 to 74 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | 0.7 | . | . | . | . | . | . |
| Age: 75 years or older | Value | 2025 | . | . | . | 0.0 | 0.0 | 0.1 | . | . | . | . | . | . |
| Age: 75 years or older | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 0.0 | . | . | . | . | . | . |
| Age: 75 years or older | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | 0.7 | . | . | . | . | . | . |
| Age: 0 to 11 years | Value | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 0 to 11 years | Lower bound 95% confidence interval | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 0 to 11 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | . | . | . | . | . | . | . |
| Age: 12 to 17 years | Value | 2025 | . | . | . | 0.5 | 0.9 | 1.0 | . | . | . | . | . | . |
| Age: 12 to 17 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.4 | 0.5 | . | . | . | . | . | . |
| Age: 12 to 17 years | Upper bound 95% confidence interval | 2025 | . | . | . | 1.6 | 2.0 | 2.2 | . | . | . | . | . | . |
| Age: 18 years or older | Value | 2025 | . | . | . | 0.1 | 0.4 | 7.0 | . | . | . | . | . | . |
| Age: 18 years or older | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.2 | 6.4 | . | . | . | . | . | . |
| Age: 18 years or older | Upper bound 95% confidence interval | 2025 | . | . | . | 0.2 | 0.6 | 7.7 | . | . | . | . | . | . |
| Origin country: The Netherlands | Value | 2025 | . | . | . | 0.0 | 0.3 | 6.8 | . | . | . | . | . | . |
| Origin country: The Netherlands | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.2 | 6.1 | . | . | . | . | . | . |
| Origin country: The Netherlands | Upper bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.5 | 7.5 | . | . | . | . | . | . |
| Origin country: Europe (excl. NL) | Value | 2025 | . | . | . | 0.0 | 0.0 | 6.1 | . | . | . | . | . | . |
| Origin country: Europe (excl. NL) | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 4.4 | . | . | . | . | . | . |
| Origin country: Europe (excl. NL) | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | 8.5 | . | . | . | . | . | . |
| Origin country: outside Europe | Value | 2025 | . | . | . | 0.5 | 1.0 | 5.9 | . | . | . | . | . | . |
| Origin country: outside Europe | Lower bound 95% confidence interval | 2025 | . | . | . | 0.2 | 0.6 | 4.7 | . | . | . | . | . | . |
| Origin country: outside Europe | Upper bound 95% confidence interval | 2025 | . | . | . | 1.1 | 1.8 | 7.4 | . | . | . | . | . | . |
| Origin: born in the Netherlands | Value | 2025 | . | . | . | 0.1 | 0.5 | 7.2 | . | . | . | . | . | . |
| Origin: born in the Netherlands | Lower bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.3 | 6.6 | . | . | . | . | . | . |
| Origin: born in the Netherlands | Upper bound 95% confidence interval | 2025 | . | . | . | 0.3 | 0.7 | 7.9 | . | . | . | . | . | . |
| Origin: born in NL, parents in NL | Value | 2025 | . | . | . | 0.0 | 0.3 | 6.8 | . | . | . | . | . | . |
| Origin: born in NL, parents in NL | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.2 | 6.1 | . | . | . | . | . | . |
| Origin: born in NL, parents in NL | Upper bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.5 | 7.5 | . | . | . | . | . | . |
| Origin: born in NL, parent(s) abroad | Value | 2025 | . | . | . | 0.7 | 1.4 | 10.0 | . | . | . | . | . | . |
| Origin: born in NL, parent(s) abroad | Lower bound 95% confidence interval | 2025 | . | . | . | 0.3 | 0.8 | 8.1 | . | . | . | . | . | . |
| Origin: born in NL, parent(s) abroad | Upper bound 95% confidence interval | 2025 | . | . | . | 1.6 | 2.5 | 12.4 | . | . | . | . | . | . |
| Origin: born in NL, parent(s) in Europe | Value | 2025 | . | . | . | 0.0 | 0.0 | 6.4 | . | . | . | . | . | . |
| Origin: born in NL, parent(s) in Europe | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 3.9 | . | . | . | . | . | . |
| Origin: born in NL, parent(s) in Europe | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | 10.4 | . | . | . | . | . | . |
| Origin: born NL, parent(s) out. Europe | Value | 2025 | . | . | . | 1.0 | 2.2 | 12.1 | . | . | . | . | . | . |
| Origin: born NL, parent(s) out. Europe | Lower bound 95% confidence interval | 2025 | . | . | . | 0.4 | 1.2 | 9.5 | . | . | . | . | . | . |
| Origin: born NL, parent(s) out. Europe | Upper bound 95% confidence interval | 2025 | . | . | . | 2.5 | 4.0 | 15.3 | . | . | . | . | . | . |
| Origin: born abroad | Value | 2025 | . | . | . | 0.1 | 0.2 | 3.3 | . | . | . | . | . | . |
| Origin: born abroad | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 2.3 | . | . | . | . | . | . |
| Origin: born abroad | Upper bound 95% confidence interval | 2025 | . | . | . | 0.8 | 0.7 | 4.6 | . | . | . | . | . | . |
| Origin: born in Europe (excl. NL) | Value | 2025 | . | . | . | 0.0 | 0.0 | 5.9 | . | . | . | . | . | . |
| Origin: born in Europe (excl. NL) | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 3.7 | . | . | . | . | . | . |
| Origin: born in Europe (excl. NL) | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | 9.1 | . | . | . | . | . | . |
| Origin: born outside Europe | Value | 2025 | . | . | . | 0.2 | 0.3 | 2.0 | . | . | . | . | . | . |
| Origin: born outside Europe | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.1 | 1.2 | . | . | . | . | . | . |
| Origin: born outside Europe | Upper bound 95% confidence interval | 2025 | . | . | . | 1.2 | 1.1 | 3.5 | . | . | . | . | . | . |
| Position: single; < 40 year | Value | 2025 | . | . | . | 0.3 | 1.6 | 22.4 | . | . | . | . | . | . |
| Position: single; < 40 year | Lower bound 95% confidence interval | 2025 | . | . | . | 0.1 | 0.8 | 18.8 | . | . | . | . | . | . |
| Position: single; < 40 year | Upper bound 95% confidence interval | 2025 | . | . | . | 1.3 | 3.3 | 26.5 | . | . | . | . | . | . |
| Position: single; 40 to 64 years | Value | 2025 | . | . | . | 0.3 | 0.6 | 5.5 | . | . | . | . | . | . |
| Position: single; 40 to 64 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.2 | 3.8 | . | . | . | . | . | . |
| Position: single; 40 to 64 years | Upper bound 95% confidence interval | 2025 | . | . | . | 1.9 | 2.0 | 8.0 | . | . | . | . | . | . |
| Position: single; >= 65 years | Value | 2025 | . | . | . | 0.0 | 0.0 | 0.1 | . | . | . | . | . | . |
| Position: single; >= 65 years | Lower bound 95% confidence interval | 2025 | . | . | . | 0.0 | 0.0 | 0.0 | . | . | . | . | . | . |
| Position: single; >= 65 years | Upper bound 95% confidence interval | 2025 | . | . | . | . | . | 0.9 | . | . | . | . | . | . |
| Position: child<18 yrs one-parent | Value | 2025 | . | . | . | 1.7 | 2.7 | 3.7 | . | . | . | . | . | . |
| Position: child<18 yrs one-parent | Lower bound 95% confidence interval | 2025 | . | . | . | 0.2 | 0.7 | 1.1 | . | . | . | . | . | . |
| Position: child<18 yrs one-parent | Upper bound 95% confidence interval | 2025 | . | . | . | 11.3 | 10.7 | 11.3 | . | . | . | . | . | . |
| Positon: child of age, one-parent househ | Value | 2025 | . | . | . | 1.4 | 2.1 | 17.3 | . | . | . | . | . | . |
| Positon: child of age, one-parent househ | Lower bound 95% confidence interval | 2025 | . | . | . | 0.3 | 0.7 | 11.6 | . | . | . | . | . | . |
| Positon: child of age, one-parent househ | Upper bound 95% confidence interval | 2025 | . | . | . | 5.3 | 6.2 | 25.1 | . | . | . | . | . | . |
| Position: child < 18 yrs, two-parents | Value | 2025 | . | . | . | 0.0 | 0.3 | 0.3 | . | . | . | . | . | . |
| Source: CBS. | ||||||||||||||
Table explanation
This table contains data on life style of the Dutch population in private households. These data can be grouped by several personal characteristics.
Data available from: 2014.
Status of the data: final.
Changes by March 13, 2026:
The figures for 2025 have been added. The table has been expanded with information on 'Drug use, excluding cannabis' and 'Use of drugs, total' (in the past month, past year, and ever). Finally, the personal characteristic of poverty (categorized as poor, almost poor, and not poor and not almost poor) has been added.
When will new data be published?
Data on reporting year 2026 will be published in the second quarter of 2027.
Description topics
- Drug use, 12 years or older
- The questions about drug use are asked to all persons aged 12 or older. The following drug types are asked whether they have ever been used and, if so, when was the last time:
• Cannabis (hashish, weed, marijuana)
• Amphetamine (such as pep and speed)
• XTC (ecstasy, MDMA)
• LSD
• Magic mushrooms (hallucinogenic mushrooms)
• Cocaine (also crack, basecoke, freebase)
• Heroine (horse, smack or brown)
• GHB or GBL
• Methadone (included in the questionnaire up to and including 2022)
• 4-Fluoroamphetamine (4-FA, 4-FMP or Flux) (included in the questionnaire from 2018 up to and including 2022)
• Ketamine (included in the questionnaire from 2023)
• 3-MMC (Poes or 3M) (included in the questionnaire from 2023)
• Laughing gas (figures in the table from reporting year 2023 onwards)
• Other drugs
The answer categories for each type of drug are:
• Yes, in the last 30 days
• Yes, in the last 12 months, but not in the last 30 days
• Yes, more than 12 months ago
• No, never used- Drugs excluding cannabis, laughing gas
- Drug use other than cannabis and laughing gas
Based on the questions about the use of:
• Amphetamine (such as pep and speed)
• XTC (ecstasy, MDMA)
• Cocaine (also crack, basecoke, freebase)
• LSD
• Magic mushrooms (hallucinogenic mushrooms)
• Heroine (horse, smack or brown)
• GHB or GBL
• Methadone (included in the questionnaire up to and including 2022)
• 4-Fluoroamphetamine (4-FA, 4-FMP or Flux) (included in the questionnaire from 2018 up to and including 2022)
• Ketamine (included in the questionnaire from 2023)
• 3-MMC (Poes or 3M) (included in the questionnaire from 2023)
• Other drugs
It involves the use of 1 or more of these types of drugs. When using several of these types of drugs, the most recently used type of drug is seen as determining the distribution across the categories 'last month', 'last year' and 'ever'.- Last month
- Last year
- Ever
- Use of laughing gas
- Based on the question on the use of laughing gas.
- Last month
- Last year
- Ever
- Other drugs excluding laughing gas
- Based on the questions about the use of:
• LSD
• Magic mushrooms (hallucinogenic mushrooms)
• Heroine (horse, smack or brown)
• GHB or GBL
• Methadone (included in the questionnaire up to and including 2022)
• 4-Fluoroamphetamine (4-FA, 4-FMP or Flux) (included in the questionnaire from 2018 up to and including 2022)
• Ketamine (included in the questionnaire from 2023)
• 3-MMC (Poes or 3M) (included in the questionnaire from 2023)
• Other drugs
It involves the use of 1 or more of these types of drugs. When using several of these types of drugs, the most recently used type of drug is seen as determining the distribution across the categories 'last month', 'last year' and 'ever'.- Last month
- Last year
- Ever
- Drugs total, excluding laughing gas
- Based on the questions about the use of:
• Cannabis (hashish, weed, marijuana)
• Amphetamine (such as pep and speed)
• XTC (ecstasy, MDMA)
• LSD
• Magic mushrooms (hallucinogenic mushrooms)
• Cocaine (also crack, basecoke, freebase)
• Heroine (horse, smack or brown)
• GHB or GBL
• Methadone (included in the questionnaire up to and including 2022)
• 4-Fluoroamphetamine (4-FA, 4-FMP or Flux) (included in the questionnaire from 2018 up to and including 2022)
• Ketamine (included in the questionnaire from 2023)
• 3-MMC (Poes or 3M) (included in the questionnaire from 2023)
• Other drugs
It involves the use of 1 or more of these types of drugs. When using multiple types of drugs, the most recently used type of drug is seen as determining the distribution across the categories 'last month', 'last year' and 'ever'.- Last month
- Last year
- Ever